E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/25/2005 in the Prospect News Biotech Daily.

Amazon Biotech announces trial of HIV/AIDS drug

New York, Oct. 25 - Amazon Biotech, Inc. said it has agreed with an AIDS clinic in New York City to do a 40-patient double-blind stuffy of AMZ 0026 together with and in comparison with the standard cocktail currently given to patients with aids.

AMZ 0026 is Amazon's first drug.

Amazon is a New York-based natural plant pharmaceutical company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.